Generalized pustular psoriasis after systemic corticosteroid withdrawal has been a concern,(4) although with little supportive evidence. In 2009, 4 cases of serious pustular psoriasis after glucocorticoid withdrawal were reported. (5) 
Intra-articular steroids
As suggested by other reviews, (6, 7) corticosteroid joint injections are based on theoretical arguments and clinical experience, more than on clinical trials and their use is less standardized compared to other therapies. Only one prospective observational study was found, (8) which evaluated 133 patients, most of them with polyarthritis (79 received one injection and 54 received >1). Clinical response (absence of tenderness or effusion) at 3 months was obtained in 41.6% of injected joints and was associated with the use of DMARDs.
The relapse rate after 12 months was 25.5% and was associated with large joints and elevated ESR. (8) 
Disease-modifying Antirheumatic Drugs (DMARDs)
Although traditional DMARDs are used for the treatment of PSA, the evidence base for their effectiveness is not well established.
Methotrexate
Since 2003, two RCTs have been published on methotrexate (MTX), the most frequently used of the DMARDs. (9, 10) In a randomized 6-month open-label trial of patients with early PsA (oligoarthritis of <12 weeks duration), (9) patients were randomized to NSAID alone or NSAID plus MTX for 3 months; thereafter, all patients continued with NSAID/MTX. Outcomes assessed at 3 and 6 months showed significant improvement in joint count and CRP/ESR in both groups at 3 months compared with baseline; improvements continued at 6 months.
Patients randomized to MTX had significantly (p<0.05) better joint count responses at 3 months compared with NSAID-alone patients, but the results were similar at 6 months when both groups were taking NSAID/MTX.
In the MIPA (Methotrexate In Psoriatic Arthritis) study, (10) 221 patients were randomized to MTX (target dose 15 mg/wk) or placebo in a 6-month RCT. Only 65% and 69% of patients in the active and placebo groups, respectively, completed the trial. At 6 months, there was improvement on the Psoriatic Arthritis Response Criteria (PsARC; primary outcome) in both groups compared to baseline, but no statistically significant differences were observed between 04 although PsA patients tended to have less improvement than RA patients. Evaluation of the retention rate of a drug provides an indirect way to evaluate its efficacy and toxicity. In this study, 2-year retention rates of MTX therapy in PsA and RA patients were 65% and 66%, respectively. (15) In an open-label study in which 115 PsA patients with relatively mild disease were randomized to receive MTX vs MTX plus infliximab, ACR 20/50/70 responses were observed in 67%, 40%, and 19%, respectively, in MTX monotherapy-treated patients, lower than combination therapy (discussed below), but still with apparent effect.(16)
Leflunomide
In a 24-week RCT of 186 patients, leflunomide was significantly superior to placebo in improvement in the PsARC (59% vs 30%, respectively) as well as tender and swollen joint scores, HAQ, and Dermatology Qualitiy of Life (DLQI) ).(17) Effect sizes were medium or small ( In a prospective, multinational 24-week observational study involving adult patients with active PsA who initiated treatment with leflunomide, 380/440 (86.4%) patients achieved a PsARC response at 24 weeks. Significant improvements were also seen in tender and swollen joint counts, patient and physician global assessments, fatigue, pain, skin disease, dactylitis, and nail lesions. The discontinuation rate was 12.3%. (18) 
Cyclosporine
No RCTs have compared cyclosporine (CSA) with placebo. In a 12-month RCT, 72 patients with active PsA and incomplete response to MTX were randomized to MTX plus either CSA or placebo. The CSA/MTX group had significant differences in synovitis (detected by ultrasound) and PASI scores; Table 1 shows small effect sizes for major outcomes. (19) Table 1 for effect sizes.)
Anti-Tumor Necrosis Factor (TNF) Therapies
In another analysis of the ADEPT trial, adalimumab monotherapy was as effective as adalimumab plus MTX in improving joint and skin patient-reported outcomes. (27) In a 12-week, RCT, where 100 patients with active PsA and inadequate response to DMARDs received adalimumab (40 mg eow) or placebo,(28) adalimumab significantly reduced joint signs and symptoms and improved skin and disability. (See Table 1 
Other Biological Disease-modifying Anti-rheumatic Drugs

Ustekinumab
Ustekinumab, a mAb directed against the p40 subunit of IL-12 and IL-23, is the only nonanti-TNFi biologic therapy approved in many countries for use in PsA. The first RCT of ustekinumab (90 mg weekly) versus placebo was conducted in 146 patients with active PsA, and psoriasis.(39) At week 12, ACR20 responses were achieved by 42% ustekinumab vs 14% placebo patients, respectively (p=0·0002). Of 124 participants (85%) with psoriasis affecting ≥3% body surface area (BSA), the PASI75 was achieved by 52% ustekinumab vs 5% placebo patients, respectively (p<0.0001). (39, 40) In an RCT (PSUMMIT 1), 615 PsA patients received ustekinumab 45 Ustekinumab has been previously discussed. (39) Within the more recent RCTs, (41, 44) approximately 50% of patients were using concomitant MTX at baseline. At week 24, ACR20 response was achieved regardless of concomitant MTX therapy or body weight, although the treatment difference appeared numerically larger in patients not receiving MTX versus those receiving MTX and in patients weighing >100 kg vs ≤100 kg, in both cases due to a higher placebo response rate in patients receiving MTX or weighing ≤100 kg. Inhibition of radiographic progression was observed for ustekinumab versus placebo, regardless of concomitant MTX status. (55) In a number of studies, MTX was combined with an anti-TNF agent. In a prospective Other studies of anti-TNF agents have shown neither additional improvement in clinical response with concomitant MTX nor an increase in adverse events. (23, 58) Two studies of adalimumab plus/minus concomitant MTX demonstrated that combination therapy resulted in similar clinical efficacy (ACR20/50/70) and radiographic improvements as adalimumab monotherapy. (23, 26) Several small studies of infliximab with continuing MTX (59) or infliximab/MTX (58, (60) (61) (62) (63) demonstrated the combination to be safe; however, study designs did not compare combination treatment with infliximab monotherapy. RCTs of infliximab similarly showed no significant difference in ACR20 when MTX was taken concomitantly. (30, 31) In a recent open-label study, 
